Loading company…
Metagen Therapeutics develops microbiome-based healthcare services and therapies, including fecal microbiota transplantation.
Founded in 2020 and based in Yamagata, Japan, Metagen Therapeutics develops microbiome-based treatments and drugs using fecal microbiota transplantation and donor-recipient matching. Its work spans ulcerative colitis, immuno-oncology and neurodegenerative disease. In September 2026, it raised JPY 500 million in Series B funding from 15th Rock, Tokai Innovation Institute and GLIN Impact Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in